tion with the Comprehensive Assessment of the Long-Term Effects of Restricting Intake of Energy (CALERIE) pilot research project, conducted at Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
, Boston, MA. The one-year, randomized and well-controlled trial included high or low glycemic load calorie-restricted diets that were provided for the first six months, followed by extensive dietary guidance for the following six months. Body-weight, fat mass, resting metabolic rate (RMR) and insulin sensitivity were measured at baseline, 3, 6, 9 and 12 months. Compliance to the diet was monitored using the double-labeled water technique for the above five time-points of the study. Interleukin Genetics, Inc. performed the genetic analysis for this study.
According to the Centers for Disease Control and Prevention (CDC) more than 72 million U.S. adults and 16 percent of U.S. children are obese, while obesity-related health care costs have totaled over $100 billion. Obesity rates among all groups in society -- irrespective of age, sex, race, ethnicity, socioeconomic status, education level, or geographic region -- have increased markedly. Obesity is a significant global health problem and it has been associated with increased risk of several co-morbidities, such as Type 2 diabetes, cardiovascular disease and osteoarthritis. Inflammatory gene polymorphisms have been previously associated with body fat mass and implicated in inducing insulin resistance.
About Interleukin Genetics
Interleukin Genetics, Inc. (NYSE: Alternext US: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive
Page: 1 2 3 Related medicine news :1
|SOURCE Interleukin Genetics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants2
. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results3
. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference4
. Interleukin-12 indicates survival prospects for melanoma patients5
. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster6
. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results7
. T cell immunity enhanced by timing of interleukin-7 therapy8
. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences9
. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 710
. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes11
. Beta Release of a New Genetics Website- ItRunsInMyFamily.com